DKFZ recruits postdoc to push bicyclic peptide radiotheranostics toward the clinic
The German Cancer Research Center is opening a postdoctoral position centered on the preclinical development of bicyclic peptides for nuclear medicine, a signal that peptide-based radiotheranostics continue to move deeper into translational oncology. The role sits within the DKTK partner site in Freiburg and is embedded in a long-term collaboration with Bicycle Therapeutics, with the explicit aim of advancing tumor-targeting radiolabeled conjugates from experimental design toward clinical translation.
The project sits at the intersection of chemistry, imaging, and cancer therapy. In practical terms, that means the work is not limited to making compounds in the lab; it spans the entire early translational chain, from solid-phase peptide synthesis and bioconjugation to labeling with clinically relevant radioisotopes and testing in vitro and in vivo. The division involved in the project describes its broader mission as the development and clinical translation of novel radiopharmaceuticals for molecular imaging and targeted radionuclide therapy.
For nuclear medicine, that combination matters because the same targeting scaffold can potentially serve two functions: identifying disease with PET and delivering therapeutic radiation to tumor tissue. The job description places the new postdoctoral scientist squarely in that radiotheranostic workflow, where candidate compounds are characterized not just for whether they bind, but for whether they can survive the path from synthesis to biological evaluation and, eventually, first-in-human translation.
Radiolabeled peptides remain attractive because of their precision and modularity
Bicyclic peptides occupy a distinct niche in targeted oncology. Their constrained structure can support strong target engagement while still allowing chemical modification, a feature that makes them attractive for radiolabeling and for tuning pharmacologic behavior. In a translational setting, that modularity is important: the peptide core, linker chemistry, and isotope choice can each influence tumor targeting, clearance, and imaging contrast. A platform built around these variables can therefore generate a pipeline of candidates rather than a single one-off molecule.
The Freiburg program is described as a platform for identifying and evaluating novel radiopharmaceuticals for PET and radionuclide therapy. The new position belongs to a research line that has already established a collaboration framework and is now being expanded with a more continuous, purpose-driven commitment toward clinical advancement. In a field where many promising compounds stall before human testing, that kind of sustained translational infrastructure is the real asset.
The scientific scope is broad but concrete. Bicyclic peptide conjugates will be synthesized by solid-phase methods, modified through bioconjugation chemistry, and then labeled with radioisotopes suitable for clinical use. From there, the work shifts into biological assessment, where in vitro studies and in vivo experiments help define whether a candidate has the properties needed for diagnostics, therapy, or both. The postdoc will also be expected to interpret the scientific data within the work plan and communicate findings to the collaboration partner.
Translational oncology depends on chemistry that can survive biology
Radiotheranostics succeed only when the chemistry is disciplined enough to hold up in living systems. A peptide that looks elegant on paper still has to reach its target, avoid excessive off-target uptake, and generate a usable signal or therapeutic effect once labeled. This is why the preclinical phase is so unforgiving: synthesis, analytical characterization, assay design, and animal data all have to align before a candidate can justify the move to clinical testing.
That requirement explains the profile DKFZ is seeking. The preferred background includes a master’s degree and PhD in biochemistry, chemistry, pharmacy, or an equivalent field, plus experience in peptide chemistry and related analytical methods. Biological assays and in vivo experience are listed as advantageous, not incidental. The position is clearly built for someone who can move between bench chemistry and translational interpretation without losing the thread of the project.
The environment itself is presented as one of the major draws. DKFZ points to state-of-the-art equipment, international networking, and access to institutional postdoctoral and career development programs. The appointment is full time, fixed term, and initially limited to two years, with the possibility of extension. Compensation follows TV-L, including occupational pension provisions and capital-forming payments.
What the role says about the direction of peptide-based nuclear medicine
Jobs like this often reveal where a research field thinks the next clinically meaningful step will come from. Here, the signal is clear: peptide radiopharmaceuticals are being pursued not as isolated tracers but as a more integrated diagnostic and therapeutic strategy. The combination of bicyclic peptide chemistry, radioisotope labeling, and preclinical characterization reflects a broader movement in oncology toward precision-delivered radiation rather than nonspecific exposure.
The collaboration with Bicycle Therapeutics adds another layer of translational intent. A sustained academic-industry partnership can accelerate the difficult middle ground between target discovery and clinical readiness, especially when the work requires repeated iteration across chemistry, imaging, and biological testing. In that sense, the postdoctoral role is less a routine lab appointment than a place inside a translational pipeline built to generate candidates with a real path forward.
The posting closes with a standard but consequential operational note: the application must go through the online portal, with no e-mail submissions accepted and no postal returns of materials. The deadline is November 5, 2026. Behind those administrative details sits a larger scientific point — peptide-based radiotheranostics are still early enough that the quality of preclinical development will largely determine which candidates ever reach patients.